LT2447254T - Kristalai - Google Patents

Kristalai

Info

Publication number
LT2447254T
LT2447254T LTEP10792183.5T LT10792183T LT2447254T LT 2447254 T LT2447254 T LT 2447254T LT 10792183 T LT10792183 T LT 10792183T LT 2447254 T LT2447254 T LT 2447254T
Authority
LT
Lithuania
Prior art keywords
crystals
Prior art date
Application number
LTEP10792183.5T
Other languages
English (en)
Inventor
Hideyuki Itou
Original Assignee
Nippon Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43386634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2447254(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co., Ltd. filed Critical Nippon Shinyaku Co., Ltd.
Publication of LT2447254T publication Critical patent/LT2447254T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
LTEP10792183.5T 2009-06-26 2010-06-25 Kristalai LT2447254T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009151727 2009-06-26
JP2009151728 2009-06-26
JP2009151729 2009-06-26
PCT/JP2010/060798 WO2010150865A1 (ja) 2009-06-26 2010-06-25 結晶

Publications (1)

Publication Number Publication Date
LT2447254T true LT2447254T (lt) 2018-01-10

Family

ID=43386634

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP17186415.0T LT3275871T (lt) 2009-06-26 2010-06-25 Kristalai
LTEP10792183.5T LT2447254T (lt) 2009-06-26 2010-06-25 Kristalai
LTPA2018008C LTC2447254I2 (lt) 2009-06-26 2018-04-18 Kristalai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP17186415.0T LT3275871T (lt) 2009-06-26 2010-06-25 Kristalai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTPA2018008C LTC2447254I2 (lt) 2009-06-26 2018-04-18 Kristalai

Country Status (33)

Country Link
US (4) US8791122B2 (lt)
EP (3) EP3689855A1 (lt)
JP (1) JPWO2010150865A1 (lt)
KR (2) KR20170024165A (lt)
CN (2) CN102459198B (lt)
AR (1) AR077242A1 (lt)
AU (1) AU2010263569B2 (lt)
BR (2) BR122021005510B1 (lt)
CA (1) CA2764475C (lt)
CL (1) CL2011003264A1 (lt)
CO (1) CO6430432A2 (lt)
CY (3) CY1119788T1 (lt)
DK (2) DK3275871T3 (lt)
ES (2) ES2797124T3 (lt)
HK (1) HK1244788A1 (lt)
HR (2) HRP20180171T1 (lt)
HU (3) HUE048467T2 (lt)
IL (3) IL216928A (lt)
LT (3) LT3275871T (lt)
MA (1) MA33637B1 (lt)
MX (2) MX346318B (lt)
MY (1) MY186531A (lt)
NO (2) NO2447254T3 (lt)
NZ (1) NZ597352A (lt)
PH (2) PH12015502825A1 (lt)
PL (2) PL3275871T3 (lt)
PT (2) PT2447254T (lt)
RU (1) RU2556206C3 (lt)
SG (2) SG176915A1 (lt)
SI (2) SI2447254T1 (lt)
TW (1) TWI531565B (lt)
WO (1) WO2010150865A1 (lt)
ZA (1) ZA201109099B (lt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101581059B1 (ko) * 2008-02-28 2015-12-30 니뽄 신야쿠 가부시키가이샤 섬유화 억제제
JP5609643B2 (ja) * 2008-07-23 2014-10-22 東レ株式会社 慢性腎不全処置剤
CN106279047B (zh) 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2016193994A1 (en) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Amorphous selexipag and process for preparation thereof
WO2017029594A1 (en) * 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Processes for preparation of selexipag and its amorphous form
US10188648B2 (en) 2015-09-03 2019-01-29 Teva Pharmaceuticals International Gmbh Solid state forms of selexipag
WO2017042828A2 (en) * 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
WO2017042731A1 (en) 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
UA124002C2 (uk) * 2015-12-02 2021-07-07 Ніппон Сіняку Ко., Лтд. Твердий препарат, що містить 2-{4-[n-(5,6- дифенілпіразин-2-іл)-n-ізопропіламіно]бутилокси}-n-(метилсульфоніл)ацетамід
WO2017109772A1 (en) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Amorphous form of selexipag
EP3192502A1 (en) 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
ES2911531T3 (es) * 2016-04-01 2022-05-19 Honour R&D Procedimiento para la preparación de los derivados de difenilpirazina
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
EP3481807A4 (en) * 2016-07-05 2020-01-15 Maithri Drugs Private Limited NEW PROCESS FOR THE PREPARATION OF 2- {4 - [(5,6-DIPHENYL PYRAZIN-2-YL) (ISOPROPYL) AMINO] BUTOXY} -N- (METHYLSULFONYL) ACETAMIDE AND NEW POLYMORPHS THEREOF
WO2018015974A1 (en) 2016-07-20 2018-01-25 Mylan Laboratories Limited Polymorphic forms and amorphous solid dispersion of selexipag
WO2018022704A1 (en) * 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Crystalline form vi of selexipag
WO2018078383A1 (en) 2016-10-27 2018-05-03 Cipla Limited Pharmaceutical composition comprising amorphous selexipag
CN108069914A (zh) * 2016-11-17 2018-05-25 江苏艾立康药业股份有限公司 一种西里帕格晶型的制备方法
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
JP2020528900A (ja) 2017-07-27 2020-10-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 体脂肪低減のためのプロスタサイクリン受容体アゴニスト
UA126928C2 (uk) 2017-09-28 2023-02-22 Ніппон Сіняку Ко., Лтд. Кристалічна форма 2-{4-[n-(5,6-дифенілпіразин-2-іл)-n-ізопропіламіно]бутилоксі}оцтової кислоти
US11382912B2 (en) 2017-11-16 2022-07-12 Nippon Shinyaku Co., Ltd. Controlled-release preparation
US10407396B2 (en) 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
JP2021512902A (ja) 2018-02-07 2021-05-20 メッドシャイン ディスカバリー インコーポレイテッド プロスタサイクリン受容体アゴニスト
CA3091584A1 (en) * 2018-02-21 2019-08-29 Nippon Shinyaku Co., Ltd. Granular composition, production method for granular composition, and dissolution property improvement method for granular composition
CN109125325B (zh) 2018-09-25 2021-05-25 中国人民解放军总医院 前列环素受体激动剂的医药用途
EP3705115B1 (en) 2019-03-07 2021-06-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition containing selexipag
JP2022532076A (ja) 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法
US20220257594A1 (en) 2019-05-21 2022-08-18 Actelion Pharmaceuticals Ltd Transitioning patients treated for pulmonary arterial hypertension to selexipag
WO2020249602A1 (en) 2019-06-11 2020-12-17 Actelion Pharmaceuticals Ltd Methods for treating pulmonary arterial hypertension
WO2021023271A1 (zh) * 2019-08-06 2021-02-11 南京明德新药研发有限公司 作为前列环素受体激动剂的化合物的晶型及其制备方法
EP4048235A1 (en) 2019-10-23 2022-08-31 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag
BR112022010311A2 (pt) 2019-11-29 2022-08-16 Actelion Pharmaceuticals Ltd Métodos de tratamento de hipertensão arterial pulmonar
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
US20230113077A1 (en) 2020-01-31 2023-04-13 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
JP2023512266A (ja) 2020-02-03 2023-03-24 アクテリオン ファーマシューティカルズ リミテッド セレキシパグを用いて肺動脈性高血圧症を治療及び評価する方法
CN112500358B (zh) * 2020-11-18 2022-03-15 江苏豪森药业集团有限公司 赛乐西帕晶型及其制备方法
WO2022106621A1 (en) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Selexipag for use via intracolonic administration
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1157187C (zh) 1999-05-10 2004-07-14 东丽株式会社 肾衰竭治疗剂
US20030092760A1 (en) 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
ES2211738T3 (es) 2000-08-03 2004-07-16 Pfizer Products Inc. Derivados de diazabiciclooctano y sus usos terapeuticos.
WO2002085412A1 (fr) * 2001-04-18 2002-10-31 Fujisawa Pharmaceutical Co., Ltd. Inhibiteurs de la fibrose des tissus
TWI316055B (lt) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
CN1787824A (zh) 2003-06-25 2006-06-14 有限会社循环器研究所 性交功能改善用外用制剂
US7112393B2 (en) 2003-07-29 2006-09-26 Canon Kabushiki Kaisha Non-magnetic toner
KR101581059B1 (ko) 2008-02-28 2015-12-30 니뽄 신야쿠 가부시키가이샤 섬유화 억제제
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
SI2292231T1 (sl) 2008-06-23 2016-03-31 Nippon Shinyaku Co., Ltd. Terapevtsko sredstvo za stenozo spinalnega kanala
ES2611483T3 (es) 2008-06-23 2017-05-09 Nippon Shinyaku Co., Ltd. Agente terapéutico para enfermedad inflamatoria intestinal
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
JP5609643B2 (ja) 2008-07-23 2014-10-22 東レ株式会社 慢性腎不全処置剤
JP5468007B2 (ja) 2008-09-10 2014-04-09 旭硝子株式会社 新規なプロスタグランジンｉ２誘導体

Also Published As

Publication number Publication date
IL216928A0 (en) 2012-02-29
ES2660007T3 (es) 2018-03-20
PH12015502825B1 (en) 2017-12-11
CA2764475A1 (en) 2010-12-29
ES2797124T3 (es) 2020-12-01
NO2018015I1 (no) 2018-04-23
PL2447254T3 (pl) 2018-05-30
PT3275871T (pt) 2020-04-21
IL243293A0 (en) 2016-02-29
AU2010263569A1 (en) 2012-02-02
DK2447254T3 (en) 2018-01-15
US9284280B2 (en) 2016-03-15
CY1119788T1 (el) 2018-06-27
HRP20180171T1 (hr) 2018-03-09
PL3275871T3 (pl) 2020-07-27
LT3275871T (lt) 2020-05-11
HUE048467T2 (hu) 2020-07-28
US20120101276A1 (en) 2012-04-26
US8791122C1 (lt) 2014-07-29
EP2447254B1 (en) 2017-12-06
SG176915A1 (en) 2012-01-30
CN102459198B (zh) 2014-09-24
IL243287B (en) 2021-04-29
TW201111352A (en) 2011-04-01
HUE036721T2 (hu) 2018-07-30
SI2447254T1 (en) 2018-03-30
BRPI1015936B1 (pt) 2021-07-13
MX346318B (es) 2017-03-15
CY1122893T1 (el) 2021-05-05
CL2011003264A1 (es) 2012-07-06
KR20170024165A (ko) 2017-03-06
JPWO2010150865A1 (ja) 2012-12-10
PT2447254T (pt) 2018-01-04
EP2447254A1 (en) 2012-05-02
LTC2447254I2 (lt) 2022-04-25
NZ597352A (en) 2013-01-25
PH12015502825A1 (en) 2017-12-11
RU2556206C2 (ru) 2015-07-10
HK1244788A1 (zh) 2018-08-17
EP2447254A4 (en) 2012-12-19
MX2011013471A (es) 2012-01-30
US8791122B2 (en) 2014-07-29
RU2556206C3 (ru) 2021-06-15
CA2764475C (en) 2017-04-25
WO2010150865A1 (ja) 2010-12-29
TWI531565B (zh) 2016-05-01
BR122021005510B1 (pt) 2022-01-11
CN104326991A (zh) 2015-02-04
CY2018011I1 (el) 2018-09-05
AU2010263569B2 (en) 2016-08-18
IL243287A0 (en) 2016-02-29
EP3275871B1 (en) 2020-01-15
CY2018011I2 (el) 2018-09-05
RU2012102678A (ru) 2013-08-10
KR20120109457A (ko) 2012-10-08
CO6430432A2 (es) 2012-04-30
US9340516B2 (en) 2016-05-17
CN102459198A (zh) 2012-05-16
HUS1800015I1 (hu) 2018-05-28
IL216928A (en) 2016-10-31
MA33637B1 (fr) 2012-10-01
ZA201109099B (en) 2012-08-29
DK3275871T3 (da) 2020-04-06
HRP20200539T1 (hr) 2020-07-10
SG10201403313WA (en) 2014-10-30
EP3275871A1 (en) 2018-01-31
SI3275871T1 (sl) 2020-06-30
US20140148469A1 (en) 2014-05-29
US9440931B2 (en) 2016-09-13
PH12015502824A1 (en) 2017-05-29
MY186531A (en) 2021-07-25
EP3689855A1 (en) 2020-08-05
AR077242A1 (es) 2011-08-10
LTPA2018008I1 (lt) 2018-05-10
NO2447254T3 (lt) 2018-05-05
US20140155414A1 (en) 2014-06-05
BRPI1015936A2 (pt) 2016-08-16
US20150266830A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
HUS1800015I1 (hu) Kristályok
ZA201105462B (en) Crystalline insulin-conjugates
HK1168791A1 (en) Substituted imidazoquinoxalines
GB201103481D0 (en) No details
GB201016096D0 (en) No details
GB201016097D0 (en) No details
HK1174617A1 (en) Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts -1----2---
EP2456311A4 (en) SUBSTITUTED IMIDASOTRIAZINES
ZA201108565B (en) Substituted piperidnes
EP2448583A4 (en) SUBSTITUTED 4-HYDROXYPYRIMIDINE-5-CARBOXAMIDES
GB0908006D0 (en) New crystal form
EP2448584A4 (en) Substituted 4-hydroxypropyl-5-carboxamide
GB2471738B (en) Floorbuddies
AU4926P (en) Bonscalib Scaevola aemula
AU4925P (en) Bonscawi Scaevola aemula
AU4924P (en) Bonscablue Scaevola aemula
AU4240P (en) Tuckerbox xTriticosecale
GB0917519D0 (en) Coroost-T706
AU2009190V (en) SILSUN Chrysocephalum apiculatum
GB0910601D0 (en) 5Locusafe
GB0900362D0 (en) Hipestone
AP00242S1 (en) Woodstove
AP2009000321S (en) Doropak
GB0903767D0 (en) Cancertest - testes
GB0913403D0 (en) Formbelt